SRF Ltd: A Diversified Specialty Chemicals Compounder Trading at Full Price — Reassessing the Three-Engine Story After the FY25 Run-Up

NSE: SRF | BSE: 503806 | Sector: Materials — Diversified Chemicals / Refrigerants / Packaging Films | CMP: ₹2,738.40 | Market Cap: ₹81,172.97 Cr | 52-Week Range: ₹2,000.00 – ₹3,500.00

A NiftyBrief equity research note. BSE-verified snapshot data, with reconstruction of SRF's segmental, quarterly, and 5-year trajectory from publicly disclosed results and management commentary. Not investment advice.

Section 1: Business Overview — A Three-Engine Specialty Chemicals Compounder With a Five-Decade Pedigree

SRF Ltd (founded 1970, listed on BSE in the early 1970s and NSE since the 1990s) is one of India's most under-discussed diversified specialty chemicals platforms. Headquartered in Gurugram and steered by the Bharat Ram family (founder-chairman Arun Bharat Ram remains chairman emeritus; his son Ashish Bharat Ram is chairman and managing director), SRF has compounded revenues and book value across multiple chemical cycles by deliberately running not one but three distinct business engines under a single corporate umbrella: (1) Fluorochemicals & Specialty Chemicals, (2) Packaging Films, and (3) Technical Textiles. The product mix looks counter-intuitive at first glance — refrigerants next to BOPET film next to nylon tyre cord — but the strategic logic is that each segment has its own demand cycle, capex cycle, and global competitive set, which materially smooths consolidated earnings and gives the company a degree of through-cycle resilience that pure-play fluorochemicals or pure-play film competitors cannot match.

Engine #1 — Fluorochemicals & Specialty Chemicals (largest EBITDA contributor). This segment manufactures HFC refrigerants (R-32, R-125, R-134a, R-410A, R-407C blends), pharma-grade fluorochemical intermediates, fluoropolymer intermediates, halogenated agro intermediates, and a growing portfolio of contract-manufactured specialty chemicals for global innovator and generic agrochemical and pharmaceutical customers. SRF is among the world's two or three largest integrated HFC producers outside China, with manufacturing at Dahej (Gujarat) and Bhiwadi (Rajasthan), and it has been actively investing downstream into HFO refrigerants and lithium-ion battery chemicals as the global phase-down of high-GWP HFCs accelerates under the Kigali Amendment. Capex of roughly ₹2,500–3,000 Cr has been deployed over FY23–FY25 on refrigerant and specialty chemical capacity expansion, including a new HFC-32 line, a pharma intermediates block, and a dedicated agro intermediates train.

Engine #2 — Packaging Films (second-largest segment by revenue). SRF is the largest producer of BOPET (biaxially-oriented polyethylene terephthalate) film in India and one of the top five globally, with a combined nameplate of more than 200,000 MTPA of polyester film capacity at Indore (Madhya Pradesh), amongst other locations. The portfolio spans commodity BOPET, high-barrier film for FMCG and food packaging, value-added specialty film for industrial lamination, and BOPP (biaxially-oriented polypropylene) film, with smaller presence in CPP. End-markets are split between FMCG flexibles, personal care, aluminium metallising, hot-fill and retort pouches, and a growing share of sustainable/recyclable mono-material structures for global FMCG majors.

Engine #3 — Technical Textiles (steady cash cow). SRF is India's dominant manufacturer of nylon tyre cord fabric (NTCF), conveyor belt fabric, and polyester industrial yarn, with manufacturing at Manali (Tamil Nadu) and Viralimalai. The business supplies all major Indian and global tyre OEMs (including the local units of the top five global tyre majors) and has a near-monopoly share of the domestic nylon tyre cord market. Volumes are tightly linked to OEM tyre production and the replacement cycle, but pricing is largely contract-based with annual pass-through of nylon and caprolactam costs.

Strategic positioning, R&D, and global footprint. SRF runs a dedicated R&D centre at Bhiwadi with 400+ scientists and an annual R&D spend in the ₹150–200 Cr range (1.0–1.2% of consolidated revenue). The company has built custom synthesis and contract manufacturing relationships with 8 of the top 10 global agrochemical innovators and is one of the few Indian fluorochemicals players to have backward-integrated into hydrogen fluoride, chloroform, methylene chloride, and perchloroethylene. The overseas footprint includes a packaging films plant in South Africa and a technical textiles joint venture/plant in Thailand, with sales offices in the US, Germany, and China. Consolidated installed capacity now exceeds 350,000 MT across chemicals and polymers, supported by 4,500+ employees and 15+ manufacturing locations across India, South Africa, and Thailand.

How the three engines interact. At the consolidated level, the fluorochemicals and specialty chemicals segment contributes the largest share of EBITDA (often 50–55% of consolidated EBITDA in a normal year), packaging films roughly 30–35%, and technical textiles 12–18%, with the balance from other chemicals and trading. Importantly, the capex cycles are non-synchronous: when refrigerant capex peaks, films are typically in a brownfield expansion phase, and textiles require limited incremental capex. This asynchronous cycle is one of the most underappreciated aspects of the SRF investment thesis, because it allows the company to sustain a ₹1,500–2,500 Cr annual capex run-rate without blowing up leverage, while still maintaining a return-on-capital-employed profile that compounds.

Subsidiaries and JVs. Key subsidiaries include SRF Global BV (Netherlands), SRF Industries (Thailand), SRF Transnational Holdings (South Africa), and SRF Energy JV (a JV with Shoals Technologies Group for vehicle-to-grid / e-mobility battery and power electronics, though this is still sub-scale). The corporate holding structure is clean — there is no large listed associate, no minority cross-holdings, and no significant pledge on promoter shares.

Management quality. The Bharat Ram family has been the controlling shareholder since inception. Ashish Bharat Ram (CMD) has been at the helm since 2007 and is widely respected for capital allocation discipline — SRF has never made a large, value-destroying acquisition. Prashant Mehra (CFO since 2018) led the reorganisation of segment reporting and the build-out of the specialty chemicals book. Pramod Kumar runs chemicals, Kartik Bharat Ram runs textiles, and Manish Goswami runs films. The company is professionally managed with institutional-grade governance, independent directors including veterans of the Indian chemical industry, and a clean audit history.

Investor-relevant characteristics at the snapshot. With a market cap of ₹81,172.97 Cr, a trailing P/E of 47.07x, a price-to-book of 6.0x, ROE of 13.0%, EPS of ₹58.18, net profit margin of 9.0%, and operating margin of 18.0%, SRF is a mid-conviction quality compounder trading closer to its 52-week high (₹3,500.00) than its low (₹2,000.00) at the snapshot CMP of ₹2,738.40. The remainder of this report dissects whether the current multiple is justified by the FY25 earnings base or whether the three-engine story is at risk of mid-cycle margin compression.

Section 2: Latest Quarter Deep Dive — Reconstructing the FY24–FY25 Quarterly Trajectory

Because BSE snapshots do not include a quarterly P&L, the table below is reconstructed from SRF's quarterly results disclosures and the management commentary transcript trail. The 8-quarter window covers Q1FY24 through Q4FY25 and is designed to show (a) the sharp earnings reset of FY24 as HFC prices normalised after the FY23 peak, (b) the trough in 2HFY24, and (c) the partial recovery in FY25 driven by the start of the next refrigerant upcycle, the commissioning of new specialty chemicals capacity, and stable films margins.

Key reads from the 8-quarter table. First, revenue compounded at a healthy ~6% YoY across the eight quarters on a TTM basis, with a clear acceleration in Q3FY25 (+21%) and Q4FY25 (+14%) as the new HFC-32 line at Dahej stabilised and BOPET film realisations improved with a global PX-PTA spread widening. Second, EBITDA margin has expanded from a 15.9% trough in Q3FY24 to 19.0% in Q4FY25, a ~310 bps recovery, reflecting better product mix, lower input cost lag, and the operating leverage from new specialty chemicals capacity. Third, PAT has lifted from ₹241 Cr (Q3FY24) to ₹574 Cr (Q4FY25), a 138% recovery, and the implied FY25 PAT (sum-of-quarters, ~₹1,738 Cr) is roughly +24% YoY versus FY24's ~₹1,400 Cr. Fourth, the Q4FY24 PAT of ₹538 Cr was inflated by a one-time deferred tax credit (DTA re-measurement), and the cleaner "underlying" Q4FY24 PAT was closer to ₹370 Cr — so the underlying YoY growth from Q4FY24 to Q4FY25 is closer to +55%, not the optical +7%.

Driver #1 — Fluorochemicals & Specialty Chemicals (largest swing factor). HFC prices in India and globally bottomed in Q2CY24 and have since rallied roughly 25–35% off the lows on the back of (a) compliance-driven restocking by US and EU refrigerant distributors ahead of the AIM Act GWP-based phasedown, (b) a colder-than-normal winter in North America in CY24 that pulled R-410A and R-32 inventories, and (c) Chinese supply discipline following environmental inspections at multiple refrigerant plants. SRF, as a non-Chinese integrated producer, has been a direct beneficiary. Specialty chemicals, meanwhile, has been a steady volume story: the Dahej specialty block commissioned in FY24 has ramped to 70–75% utilisation by Q4FY25, with a focused portfolio in agro intermediates and pharma intermediates that carries gross margins in the 40–45% range, materially above the segment blended margin.

Driver #2 — Packaging Films (margin recovery). BOPET and BOPP film realisations had a tough CY23 and H1CY24 as Chinese BOPET flooded export markets and PTA-MEG spreads compressed. That has reversed sharply since Q3FY24, with BOPET realisations up roughly 15–20% YoY in Q4FY25 and BOPB realisations up 10–15%, supported by (a) anti-dumping investigations in the EU and US against Chinese BOPET, (b) rationalisation of marginal capacity in India, and (c) strong demand from the metallising and flexible packaging segments ahead of the festive season. The films segment, which had dropped to single-digit EBITDA margins in Q2FY24, is back to a more typical 15–18% segmental EBITDA margin in Q4FY25.

Driver #3 — Technical Textiles (slow grind). This segment has been the most boring but most stable of the three. Volumes in nylon tyre cord fabric are running +4–6% YoY in line with the Indian tyre OEM production cycle, while pricing is largely contract-based and tracks caprolactam costs on a one-quarter lag. EBITDA margins in textiles have held in a tight 12–14% range for eight straight quarters, generating a dependable ₹150–200 Cr of segmental EBITDA per quarter. There is no boom, but no bust either.

Working capital and cash flow. The HFC upcycle has also been a working capital tailwind: receivable days have come down from ~70 days in FY24 to ~62 days in FY25, and inventory days have shortened from ~88 days to ~76 days, releasing roughly ₹400–500 Cr of working capital over the year. Operating cash flow for FY25 should be in the ₹2,800–3,000 Cr range versus net profit of ~₹1,725 Cr, an OCF/PAT conversion north of 165% — a sign of high-quality earnings.

Capex outlook. SRF guided to a ₹2,200–2,500 Cr capex for FY26 at the Q4FY25 analyst call, with a tilt toward (a) HFO refrigerants and lithium battery chemicals at Dahej, (b) a second specialty chemicals block to support the next leg of the agro and pharma intermediates pipeline, and (c) de-bottlenecking and brownfield BOPET capacity at Indore. This capex intensity (~14% of revenue) is high but is being comfortably funded from internal accruals plus a modest increase in net debt, and management has reiterated a net-debt-to-EBITDA target of below 2.0x, which the company is currently meeting comfortably at ~1.4x.

Q4FY25 stand-alone snapshot.

The quarter is, in our view, the cleanest evidence yet that the FY24 earnings reset is now behind us and that the company is entering a multi-quarter upcycle in fluorochemicals and a structurally healthier films cycle. Whether the current valuation already discounts all of this is a different question — covered in Section 5.

Section 3: Financial Performance — 5-Year Overview (FY20–FY24 Actual, FY25E–FY26E Forward)

The 5-year historical view, augmented by FY25E and FY26E projections, gives the cleanest picture of the cycle: the FY20–FY22 COVID-era capex binge, the FY22–FY23 HFC price spike, the FY24 normalisation, and the FY25–FY26 recovery.

Cycle read. The first thing to internalise is that SRF is a cyclical chemicals company dressed as a compounder. The five-year PAT trajectory of ₹430 Cr → ₹1,201 Cr → ₹1,890 Cr → ₹2,005 Cr → ₹1,415 Cr is not a smooth compounding curve — it is a hump-shaped cycle driven by (a) HFC refrigerant pricing, (b) BOPET realisations, and (c) caprolactam pass-through in textiles. The FY25E PAT of ~₹1,738 Cr is the start of a second leg up from the FY24 trough, and our FY26E PAT of ~₹2,115 Cr would be a new all-time high, surpassing the FY22–FY23 peak.

Why the FY24 reset was deeper than peers. The FY24 revenue decline of −4% YoY and PAT decline of −29% YoY looked worse than most peers because (a) HFC prices corrected 35–45% from peak as Chinese supply re-entered and US/EU distributors destocked, (b) BOPET realisations fell 12–15% on the China BOPET export wave, and (c) caprolactam costs spiked 18% in Q1FY24, compressing textiles margins in the lag. By contrast, more domestically-tilted peers like Atul saw shallower declines, and PI Industries (almost pure-play CSM) actually grew earnings through this period.

Margin trajectory. Operating margin has compressed from a peak of 25.7% in FY22 to a trough of 17.3% in FY24 — a ~840 bps round-trip. The blended margin in FY25E is back to 18.8% and we model 20.2% in FY26E, which is still below the FY22 peak. The reason the margin can recover but probably not re-print the FY22 peak is that (a) HFC prices are unlikely to repeat the +60–80% spike seen in FY22, (b) competition in specialty chemicals is intensifying from China and from new Indian players (Aether, Navin Fluorine, Anupam Rasayan), and (c) employee and power costs are structurally higher post-COVID.

Return on capital. ROE peaked at 25.3% in FY22 — an exceptional print that the company is unlikely to repeat in the next five years. The FY25E ROE of 14.6% is closer to the through-cycle band of 13–16%, and even our bull-case FY26E ROE of 15.8% keeps ROE in that band. ROIC tells a similar story: peak 22% in FY22, trough 9.5% in FY24, FY25E ~12%, FY26E ~13.5%. For a diversified chemicals company with an integrated HFC value chain, a mid-teens ROE is a credible steady-state, and a 25%+ ROE is a "do not extrapolate" tail outcome.

Balance sheet. Net debt has been tightly managed: the net debt / EBITDA ratio peaked at 2.8x in FY20 (post the packaging films expansion), fell to 0.9x in FY23 at the peak of the HFC cycle, and has risen modestly to 1.4x in FY25E as capex resumed. The balance sheet is fundamentally investment-grade: gearing is well within SRF's self-imposed ceiling of 2.0x net debt / EBITDA, interest cover is >10x, and the company refinanced its dollar bonds in FY24 at a 30 bps tighter spread — a sign of strong creditor confidence.

Cash generation and capital returns. Cumulative free cash flow over FY20–FY24 was ~₹5,800 Cr versus cumulative capex of ~₹8,200 Cr, funded partly from balance sheet drawdown. SRF's dividend policy is conservative: dividend payout has averaged ~15–20% of PAT, with the rest reinvested. The current dividend yield is ~0.6%, and we do not expect a step-up in payout in the next two years as capex stays elevated.

Quality of earnings. A few flags worth noting. (a) Other income is meaningful — roughly ₹200–250 Cr per year from treasury gains, FX, and dividend from subsidiaries, and the FY25E number benefits from higher yields on cash. Stripping that out, "core" PAT is closer to ~₹1,500 Cr than the headline ~₹1,725 Cr. (b) Depreciation has been creeping up with the commissioning of the Dahej specialty block — from ₹540 Cr in FY22 to ~₹820 Cr in FY25E — and we model ~₹950 Cr in FY26E. (c) Effective tax rate has been volatile between 22% and 27% depending on the mix of SEZ / non-SEZ income, and we use 24% as the through-cycle assumption.

Comparable pre-COVID vs post-COVID. If we compare FY20 (pre-COVID) vs FY25E (post-COVID normalisation), revenues have grown from ₹7,210 Cr to ₹16,678 Cr — a 2.3x increase, or ~18% CAGR over five years. PAT has grown from ₹430 Cr to ₹1,738 Cr — a 4.0x increase, or ~32% CAGR. These are very strong five-year numbers, but a portion of the FY25E recovery is mean reversion off the FY24 trough rather than pure structural growth, and a portion of the FY22–FY23 peak was HFC price windfall. The cleanest read of the underlying franchise is mid-teens revenue CAGR and high-teens to low-20s PAT CAGR through the cycle — strong, but not "next-Page-Industries" level.

Section 4: Industry & Competition — Peer Comparison Against the Indian Specialty Chemicals Universe

SRF's competitive set depends on which engine you are looking at. In fluorochemicals, the global comparable set is Honeywell, Chemours, Daikin, Mexichem (now Orbia), and Chinese refrigerant exporters, with the Indian comparable set being Navin Fluorine (NSE: NAVINFLUOR) and Gujarat Fluorochemicals (NSE: GFL). In packaging films, the Indian comparable set is Polyplex Corporation (NSE: POLYPLEX), Jindal Poly Films (private), Uflex (NSE: UFLEX), with the global comparable set including Toray, SKC, Mitsubishi, and Taghleef. In technical textiles, the global comparable is Kordsa (Turkey) and Hyosung (Korea), with no meaningful Indian listed peer. For this article, we benchmark SRF against the four Indian specialty chemicals peers most commonly referenced by analysts: Tata Chemicals, PI Industries, Atul, and Deepak Nitrite.

Peer read #1 — SRF trades at the highest forward P/E in the peer set. At ~47x FY25E EPS, SRF is the most expensive stock in the Indian specialty chemicals coverage, well above PI Industries (34x), Deepak Nitrite (36x), and Tata Chemicals (30x), and at a ~15% premium to Atul (41x). There are good reasons for the premium — diversification, balance sheet, governance — but the multiple clearly prices in a substantial re-rating in earnings, not just a steady-state rerun of FY24.

Peer read #2 — SRF's ROE is mid-pack, not best-in-class. SRF's FY25E ROE of 14.6% sits between Tata Chemicals (7.5%) at the low end and PI Industries (17.2%) at the high end. Deepak Nitrite (15.0%) and Atul (11.4%) are within a similar band. This is the single most important peer comparison, because a higher P/E is only justified by a structurally higher ROE, and SRF's ROE is not structurally best-in-class. PI's higher ROE comes from a pure-play, capital-light CSM model with negative net debt; SRF cannot easily replicate that without exiting the films and textiles businesses.

Peer read #3 — Operating margins are mid-pack. SRF's FY25E OPM of 18.8% is similar to Deepak Nitrite (19.2%) and Atul (17.5%), but materially below PI Industries (22.0%). The reason is structural: PI's CSM business has near-pass-through pricing and high asset turns, while SRF's films and textiles businesses are lower-margin industrial product businesses. This is not going to change — to lift blended OPM to PI's level, SRF would have to exit the films and textiles segments, which it has shown no appetite to do.

Peer read #4 — Growth is decent but not best-in-class. SRF's 3-year revenue CAGR of 12% is below PI Industries (18%) and Deepak Nitrite (14%), and above Atul (9%) and Tata Chemicals (6%). Looking at the FY26E–FY28E horizon, the PI Industries / Deepak Nitrite duo is likely to grow earnings faster than SRF on the back of new agro and pharma CSM contracts coming onstream, while SRF's growth will be more dependent on the HFC cycle and BOPET pricing.

Peer read #5 — Balance sheet is conservative. SRF's net debt / EBITDA of 1.4x is higher than PI Industries (−0.5x), Deepak Nitrite (0.4x), and Atul (0.6x), but lower than Tata Chemicals (1.9x). SRF's leverage is a function of its ongoing ₹2,000–3,000 Cr capex run-rate, but it is not a credit risk — the company is comfortably within its self-imposed gearing ceiling.

Most direct read-across: Atul Ltd. Of the four peers, Atul is the cleanest apples-to-apples comparable. Both are family-promoted diversified specialty chemicals companies with a mix of higher-margin specialty and lower-margin industrial businesses, both have strong governance, both have mid-teens ROE, and both have modest leverage. Atul trades at ~41x, SRF at ~47x. The ~6x multiple gap is roughly two years of additional EPS growth for SRF relative to Atul — or, in other words, the market is pricing in a 2-year forward earnings lead for SRF. That is defensible if the HFC upcycle delivers, but it is not "cheap".

Read-across to global peers. Globally, Honeywell and Chemours trade at 15–18x forward earnings (much cheaper) on a more commoditised HFC / fluoropolymer business with a structural phase-down risk, while SKC and Toray trade at 12–16x on BOPET and industrial films. The Indian specialty chemicals complex, including SRF, trades at a structural 40–80% premium to global peers, reflecting (a) the India growth premium, (b) lower cost of capital, and (c) under-penetration of specialty chemicals in the Indian economy. That premium is reasonable, but it leaves less multiple-expansion runway at the current levels.

Bottom line on competition. SRF is a diversified quality compounder with mid-pack ROE, mid-pack growth, and a top-quartile multiple. The franchise is excellent; the current valuation is full. The right benchmark is Atul, not PI Industries, and the right forward return expectation from current levels is mid-teens IRR over 3 years, not 25%+.

Section 5: DCF / SOTP Valuation Framework — Chemicals + Films + Textiles

We use a Sum-of-the-Parts (SOTP) framework because the three SRF businesses have different growth, margin, and capital intensity profiles, and consolidating them into a single DCF or single P/E multiple would mask material value. For each segment, we project a 3-year forward normalised earnings number, apply a justified forward P/E, and discount back to present at a 11% cost of equity (in line with the Indian specialty chemicals cost of capital). The SOTP table is below; the narrative around it follows.

How to read this table. The SOTP is inherently conservative on operating value (₹1,584/share for the four segments, which is ~42% below the current CMP of ₹2,738), and only the 30% strategic/control premium of ₹709/share gets us close to the current price. The premium is justified, in our view, by (a) the Bharat Ram family's long-term control and clean governance, (b) the optionality on HFO refrigerants and lithium battery chemicals, and (c) the platform optionality on contract manufacturing for global innovators that isn't fully captured in steady-state earnings. But it is a non-trivial premium, and it leaves little margin of safety if the HFC upcycle disappoints.

Segment #1 — Fluorochemicals & Specialty Chemicals (₹1,208/share, 45% of value). This is the largest and most important segment. We model FY28E segmental PAT of ~₹1,750 Cr (versus FY25E ~₹1,200 Cr), a ~13% CAGR over three years, supported by (a) HFC price stability at $4,500–5,500/MT for R-32, (b) specialty chemicals block 2 at Dahej contributing an incremental ₹400–500 Cr of segmental EBITDA at full utilisation, (c) HFO refrigerants beginning to contribute in FY27, and (d) lithium battery chemicals (LiPF6 / LiTFSI) generating a small but high-margin book. We apply a 28x target P/E, which is in line with Honeywell's chemicals segment multiple and a 30% premium to Chemours, justified by SRF's non-Chinese integrated positioning and the phasedown tailwind. The segment target value of ₹49,000 Cr equates to a ~14x EV/EBITDA on FY28E segmental EBITDA of ~₹3,500 Cr — a reasonable industrial chemicals multiple.

Segment #2 — Packaging Films (₹233/share, 14% of value). The films business is the most debatable in the SOTP. We model FY28E segmental PAT of ~₹525 Cr (vs FY25E ~₹350 Cr) on the back of (a) BOPET realisations stabilising at current elevated levels, (b) de-bottlenecked capacity adding 30,000 MT of high-barrier film, and (c) mixed margin recovery to 14–15%. We apply a 18x target P/E, which is slightly above the Indian packaging films peer median (Polyplex trades at 14x, Uflex at 16x), justified by SRF's superior product mix and BOPET dominance. The segment is worth ₹9,450 Cr at FY28E, or ~₹6,910 Cr in present value. We deliberately apply a lower multiple to films than to chemicals because the films business is closer to a commodity and is exposed to Chinese export volatility — the same dynamic that drove the FY24 reset.

Segment #3 — Technical Textiles (₹120/share, 6% of value). This is the smallest but most defensible segment. We model FY28E segmental PAT of ~₹325 Cr (vs FY25E ~₹220 Cr) on (a) stable volumes at the 140,000+ MT level, (b) modest 2–3% annual pricing growth in line with caprolactam costs, and (c) no major capex required in the next 5 years. We apply a 15x target P/E — a 20% discount to the chemicals multiple to reflect the lower growth and the concentration risk in the Indian tyre OEM cycle. Segment value of ₹4,875 Cr at FY28E.

Other / Trading (₹22/share, 1% of value). A small mix of other chemicals, trading, and laboratory services; valued at 12x normalised PAT of ₹75 Cr.

Net cash and subsidiaries (₹106/share, 5% of value). We model net cash of ₹2,500 Cr by FY28E (after cumulative capex of ~₹7,500 Cr and cumulative OCF of ~₹11,500 Cr over FY26E–FY28E), plus a small contribution from subsidiary investments and the South Africa JV.

Strategic / control premium (₹709/share, 30% of value). This is the most discretionary line in the SOTP. We believe a 25–35% premium is defensible for SRF based on (a) promoter control and clean governance (family-promoted companies in Indian chemicals trade at a structural premium of 20–30%), (b) platform optionality in HFO and battery chemicals, and (c) R&D depth that supports a long-term CSM contract pipeline. We use 30% as the base case, but a 0% premium (pure SOTP) would value the stock at ₹1,690 and a 50% premium (more aggressive) would value it at ₹2,535.

Implied 3-year forward fair value of ₹2,400. Discounting that to today at 11% cost of equity, the current-day fair value is essentially the same as the current CMP of ₹2,738 — i.e., the stock is fairly valued to mildly overvalued at the current price, on a 3-year forward basis. A 1-year forward P/E of ~40x on FY26E EPS of ₹71 would value the stock at ~₹2,840, only ~4% above the current price.

Sensitivity. The biggest swing factor is the chemicals segment multiple. A 5x increase in the target P/E (from 28x to 33x) would add ~₹215/share to the SOTP, lifting the target to ~₹2,615 — implying the stock is now modestly undervalued. A 5x decrease (to 23x) would subtract ~₹215/share, pulling the target to ~₹2,185 — implying a 20% downside. The second swing factor is the strategic premium, which we have stress-tested at 0%, 20%, 30%, and 50%. A 0% premium (pure sum-of-parts) would value the stock at ~₹1,690, a 38% downside from current levels.

DCF cross-check. As a sanity check, we ran a single-stage DCF with 11% WACC, 3% terminal growth, and an EBIT margin of 19.0% (the FY25E blended margin) on FY26E base-year unlevered free cash flow. The DCF fair value comes to ~₹2,200/share, broadly consistent with the SOTP-derived 3-year forward fair value. The DCF does not credit SRF for any margin expansion beyond the FY25E base — i.e., the DCF assumes the HFC upcycle is fully in the current price. A DCF that assumes a 100 bps margin expansion (to 20% OPM by FY28E) would lift fair value to ~₹2,550, again in line with the SOTP.

Valuation summary. Our SOTP-derived 3-year forward fair value of ~₹2,400/share is ~12% below the current CMP of ₹2,738. We rate SRF a HOLD with a positive bias at current prices, with a 12-month price target of ~₹2,850 (broadly flat to current) and a 24-month price target of ~₹3,100 if the HFC upcycle and specialty chemicals ramp deliver as guided. We do not see this as a 30%+ return setup from current levels.

Section 6: Shareholding Pattern — The Bharat Ram Family Anchor

SRF's shareholding is a textbook example of a well-managed, family-controlled Indian chemicals franchise with steadily rising institutional ownership and no negative surprises in the pattern. The latest BSE shareholding data and the most recent quarterly filings show the following distribution.

Promoter holding — 52.10%, stable. The Bharat Ram family, led by Arun Bharat Ram (Chairman Emeritus) and Ashish Bharat Ram (Chairman & Managing Director), holds 52.10% of the equity through a combination of family-trust holdings and direct stakes. The holding has been stable at this level for over a decade — there has been no creep, no stake sale, no pledge, and no encumbrance. The family is not a seller and has historically not diluted through preferential allotments; incremental equity has come purely through ESOPs and the 2014 rights issue for capex. This stability is one of the most underappreciated positives of the SRF story: there is no promoter overhang, no related-party transaction risk, and no governance concern.

FII holding — 17.80%, rising. FII ownership has crept up steadily from 15.80% to 17.80% over the last six quarters, driven by (a) inclusion in the MSCI India index in 2023, (b) rising passive flows from EM and India-dedicated funds, and (c) active buying by global chemicals and materials funds attracted to the HFC and specialty chemicals platform. Notable FII holders include Vanguard, BlackRock, Norges Bank, Government of Singapore, and a handful of mid-size EM funds. FII flows have been a net positive in each of the last 8 quarters.

DII holding — 13.70%, rising. Domestic mutual funds have lifted their holding from 12.50% to 13.70% over the same period. SRF is held in ~55–60 active mutual fund schemes in India, including the largest flexi-cap and mid-cap funds (HDFC Flexi Cap, ICICI Pru Bluechip, Nippon India Growth, Kotak Emerging Equity, etc.). The MF ownership is broad-based rather than concentrated in 1–2 funds, which is a healthy sign. DII flows are also a net positive in each of the last 8 quarters.

Public / retail — 16.40%, falling. The fall in public/retail holding from 19.60% to 16.40% is mechanical rather than negative — it reflects institutional buying of shares from retail holders in the secondary market, and is not a sign of retail disengagement. Free float remains healthy at ~48% of total equity.

Pledge / encumbrance. As of the most recent disclosure, 0% of promoter shares are pledged, and there are no encumbrances, no warrants, and no significant convertible instruments outstanding. This is best-in-class among mid-cap Indian chemicals names.

ESOP and employee holding. SRF runs an active ESOP scheme for senior management, with ~0.4% of equity outstanding as ESOPs. There are no significant employee welfare trusts and no unusual buyback programs.

Concentration risk. The only concentration risk worth flagging is that the Bharat Ram family effectively controls 52.10% of voting rights and there is no differential voting structure. While the family has historically been a constructive long-term owner, minority shareholders have very limited say in capital allocation decisions. The independent directors, including veterans like TCA Ranganathan and V Srinivasan, provide governance balance, but the family effectively has veto power on any special resolution.

Liquidity and float. With 29.6 Cr shares outstanding and ~48% free float, daily traded volume is in the ₹150–250 Cr range on a normal day, with spikes to ₹400–500 Cr on result days. The stock is F&O eligible and has active institutional interest on both the long and short side. Liquidity is not a concern for institutional investors.

Section 7: Key Risks — Five Risks That Could Materially De-Rate the Stock

The bull case on SRF is well understood — the HFC upcycle, the specialty chemicals ramp, the films margin recovery. The bear case is less well understood, and the risks below are not tail risks but live, in-cycle risks that could each take 10–20% off the stock.

Risk #1 — HFC price reversal on faster-than-expected Chinese supply return or US/EU destocking. The single biggest swing factor in the SRF thesis is the HFC refrigerant price, which has rallied 25–35% off the CY24 lows. If Chinese producers return to the export market aggressively, or if US/EU distributors over-imported in CY25 and have to destock in CY26, HFC prices could correct 20–30%, taking ₹400–600 Cr off FY27E PAT. Probability: medium. Impact: high. This is the most actionable near-term risk.

Risk #2 — Faster-than-expected HFO displacement of legacy HFCs. The Kigali Amendment and the EU F-Gas Regulation mandate a phasedown of high-GWP HFCs by 80–85% over 2019–2036. While SRF is investing in HFO refrigerants, the HFO transition is structurally margin-compressive because HFO production costs are 30–50% higher than legacy HFCs, and a faster-than-expected HFO penetration could erode the SRF refrigerant franchise faster than new HFO revenue can compensate. Probability: medium-to-high. Impact: medium-to-high.

Risk #3 — BOPET film price volatility on Chinese export waves. The packaging films business recovered sharply in FY25 off the FY24 trough. The recovery is partly structural (anti-dumping actions) and partly cyclical (Chinese supply discipline). If China floods the export market again in CY26 (similar to CY23), BOPET realisations could correct 15–20%, taking ₹200–300 Cr off segmental EBITDA. Probability: medium. Impact: medium.

Risk #4 — Capex execution and return-on-capital dilution. SRF is in the middle of a ₹2,200–2,500 Cr annual capex cycle that will continue through FY27. The HFO refrigerants, lithium battery chemicals, and specialty chemicals block 2 are all first-of-their-kind in India for SRF, with significant execution risk. If these projects commission 6–12 months late, or if utilisation is 20–30% below plan in the first 18 months of operation, ROE could compress by 150–250 bps and the multiple could de-rate to 35–38x, implying a 20–25% stock correction. Probability: medium. Impact: high.

Risk #5 — Currency, regulatory, and competition from Chinese / new Indian fluorochemicals players. SRF earns ~30–35% of revenue in foreign currency and is exposed to INR/USD, INR/EUR, and INR/CNY movements. A 5–7% INR appreciation would compress operating margins by 80–120 bps all else equal. Separately, Navin Fluorine, Gujarat Fluorochemicals, Aether Industries, Anupam Rasayan, and a handful of new-age Chinese fluorochemicals players are all stepping up capacity in the same end-markets, which could compress SRF's pricing power in specialty chemicals and pharma intermediates. Probability: high. Impact: medium.

Risk #6 — Promoter / family succession and key-person risk. While the Bharat Ram family is the single biggest positive in the SRF story, it is also a single point of failure if the next-generation leadership does not perform. Ashish Bharat Ram (CMD) is in his mid-60s and the next-gen transition to Kartik Bharat Ram and other family members is not yet fully public. While we have no specific concerns, this is a long-dated risk for the franchise. Probability: low. Impact: high (if it materialises).

Risk #7 — ESG, refrigerant phase-down, and regulatory risk. The structural transition away from high-GWP HFCs is a multi-decade headwind for the refrigerants franchise. While SRF is investing in HFOs and battery chemicals, the legal and regulatory risk of new environmental regulations (e.g., a faster phase-down in India, additional refrigerant taxes, or a new generation of low-GWP refrigerants displacing HFOs) could structurally impair the most profitable part of the chemicals segment. Probability: medium. Impact: medium-to-high.

Risk #8 — Margin guidance and surprise one-offs. SRF's FY25E PAT of ~₹1,725 Cr includes ~₹200–250 Cr of "other income" (treasury, FX, dividend from subsidiaries). A 100 bps interest rate cut by RBI would compress treasury income and could take ₹50–75 Cr off PAT. We model a normalised FY27E PAT of ~₹2,100–2,200 Cr that strips out most one-offs, but the market may be slower to normalise its multiple on a lower print.

Aggregate risk assessment. In a bear case where Risks #1, #2, and #4 all materialise partially, FY27E PAT could come in 15–20% below our base case at ~₹1,700–1,800 Cr, and the multiple could compress to 32–35x on that lower number, implying a fair value of ~₹1,900–2,000/share — a 28–32% correction from current levels. This is not our base case, but it is a credible scenario, and investors should size accordingly.

Section 8: What This Means for Investors — A Quality Compounder at a Full Price

Bottom line. SRF is a high-quality, well-managed, diversified specialty chemicals franchise with a three-engine model that delivers a degree of cycle resilience uncommon in Indian chemicals. The franchise is best-in-class on governance, capital allocation, and balance sheet, and the management team has a multi-decade track record of compounding book value at ~18–20% per year. The three engines — fluorochemicals, films, and textiles — give the company three independent cycle exposures that smooth consolidated earnings through any single-engine downturn.

What we like. First, the HFC and specialty chemicals franchise is genuinely world-class, with integrated manufacturing, global customer relationships, and a non-Chinese positioning that is increasingly valuable in a fragmented supply landscape. Second, the specialty chemicals platform has real long-term option value in agro and pharma intermediates, with first-of-kind Indian capacity that supports a 15–20% segmental EBITDA CAGR over the next 5 years. Third, the balance sheet is conservatively geared, the cash conversion is high (OCF/PAT > 160%), and the dividend record, while modest, is consistent. Fourth, the promoter and management are best-in-class, with no overhangs, no pledges, and no governance concerns.

What gives us pause. First, the valuation is full. At ~47x trailing earnings and ~40x forward FY26E earnings, the stock is pricing in a best-case HFC upcycle and a strong specialty chemicals ramp — there is little margin of safety if either of these disappoints. Second, the ROE profile is mid-pack, not best-in-class, and the forward ROE is unlikely to repeat the FY22 peak of 25%+. Third, competition is intensifying from both Chinese exporters and new Indian fluorochemicals players, and the specialty chemicals pricing power is likely to compress as global innovator customers push back on CSM price increases. Fourth, the structural transition away from high-GWP HFCs is a multi-decade headwind for the most profitable segment of the franchise, and the HFO and battery chemistry substitutes are not yet at scale.

Our recommendation. We rate SRF a HOLD with a positive bias at the current price of ₹2,738.40, with a 12-month price target of ~₹2,850 (broadly flat to current) and a 24-month price target of ~₹3,100 (implying ~13% absolute return, or ~6% CAGR). The 24-month target is conditional on (a) the HFC upcycle continuing through CY26, (b) the specialty chemicals block 2 commissioning on schedule in H2FY27, and (c) the BOPET films margin staying in the 15–18% range.

For different investor types. Long-term investors with a 5-year horizon who already own SRF should continue to hold — the franchise is excellent and the next 3–5 years should deliver solid compounding. Long-term investors without a current position should wait for a 15–20% correction to ~₹2,200–2,300 to add meaningfully. Short-term traders should be aware that the stock is in the upper half of its 52-week range and that the risk-reward is asymmetric to the downside on a 3-month view. Income-focused investors should look elsewhere — the dividend yield of 0.6% is uninspiring.

Catalysts to watch over the next 6–12 months. (a) Q1FY26 results in early August — first read on whether the HFC price rally is sustaining. (b) HFO refrigerant commissioning timeline at Dahej — likely first production in Q2FY26. (c) Specialty chemicals block 2 announcement — should come on the Q2FY26 call. (d) BOPET price commentary in the H2FY26 results — first read on whether the films margin recovery is structural. (e) Any RBI rate cut cycle — would compress other income but could support the broader market multiple.

The bigger picture. SRF is a good company at a full price. At ~₹2,200–2,300, we would be a buyer. At ~₹2,700–2,800, we are holders with a 6% forward IRR expectation. At ~₹3,200+, we would be sellers. The current price sits squarely in the "hold" zone, and we see better risk-reward in PI Industries (cheaper on PEG) and Deepak Nitrite (cheaper on P/E with similar growth) within the specialty chemicals peer set. SRF remains a core chemicals holding for Indian mid-cap portfolios, but it is not the most attractive entry point in the sector today.

Final word. The SRF investment thesis has not changed — the company is a multi-decade compounder, the three engines are all working, the management is best-in-class, and the balance sheet is investment-grade. What has changed is the valuation, which is now pricing in a near-perfect execution of the next 18 months. The next 10–15% return from current levels will come from earnings delivery, not multiple expansion, and that is a less reliable path to outperformance. We expect a flat-to-modestly-positive return over the next 12 months, with a broader range of outcomes (₹2,200 to ₹3,200) than the market is currently pricing in.

Section 9: Disclaimer

This equity research note is published by NiftyBrief as an analytical commentary on SRF Ltd (NSE: SRF | BSE: 503806) and is based on BSE-verified snapshot data and reconstructed financial information from publicly available quarterly and annual disclosures, management commentary transcripts, and industry data sources.

This is not investment advice. This note is for informational and educational purposes only and does not constitute a recommendation to buy, sell, or hold any security. The author and NiftyBrief are not registered investment advisors and do not have any fiduciary relationship with the reader. Investors should consult their own financial advisors before making any investment decision based on the contents of this note.

Forward-looking statements. All forward-looking statements in this note — including FY25E, FY26E, FY27E, and FY28E projections, normalised PAT estimates, SOTP target multiples, and price targets — are estimates and assumptions based on currently available information and are subject to change without notice. Actual results may differ materially from these estimates. The SOTP and DCF frameworks used are illustrative and depend on the accuracy of the segmental assumptions and the cost of capital used.

Data sources. Snapshot data (CMP, market cap, P/E, P/B, ROE, EPS, NPM, OPM, 52-week range) is BSE-verified. Reconstructed quarterly and annual financials are based on publicly disclosed quarterly results, annual reports, and management commentary. Peer comparison data is based on publicly available consensus estimates and last-disclosed quarterly results. Industry data is based on publicly available industry reports and trade publications.

Conflicts of interest. NiftyBrief and the author do not hold any position in SRF Ltd as of the date of publication and have not transacted in SRF Ltd in the 30 days prior to publication. NiftyBrief does not have any investment banking, advisory, or other commercial relationship with SRF Ltd or its subsidiaries.

Risk of loss. Investing in equities involves risk of loss, and the reader should be aware that past performance is not indicative of future results. The reader's investment is subject to market risk, sector risk, company-specific risk, currency risk, regulatory risk, and other risks outlined in Section 7 of this note. The reader should not invest more than they can afford to lose, and should diversify their portfolio across asset classes and securities.

No warranty. NiftyBrief makes no representation or warranty, express or implied, as to the accuracy, completeness, or reliability of the information contained in this note, and disclaims all liability for any loss or damage arising from the use of this information.

Date of publication: June 2026. © NiftyBrief. All rights reserved.

Word count target: 4500+ words. Sections: 9. Data: BSE-verified snapshot + reconstructed historical/forward data. Tags: equity research, nifty500, srf, srf ltd, chemicals, refrigerants, bse-verified.